Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arbutus Biopharma CorpABUS · Entity 4953 | Director | June 21, 2017 | June 23, 2017 |
| Better Therapeutics, Inc.BTTX · Entity 94385 | Director · Chief Executive Officer | December 18, 2023 | December 20, 2023 |
| CHINOOK THERAPEUTICS, INC.ADRO · Entity 110632 | Director | May 05, 2020 | May 28, 2020 |
| Myovant Sciences Ltd.MYOV · Entity 115677 | Principal Fin'l & Accounting | July 07, 2021 | July 09, 2021 |
| Phathom Pharmaceuticals, Inc.PHAT · Entity 5177 | Director | May 19, 2026 | May 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arbutus Biopharma Corp
Report date June 21, 2017 · Filed June 23, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.55 · Expires 2027-06-21 | Direct | 22,000 |
Reported balance
After 2017-06-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-21 · Grant · Acquired 22,000 · Balance 22,000 F1: Immediately exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: Immediately exercisable.
Better Therapeutics, Inc.
Report date December 18, 2023 · Filed December 20, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 526,516 |
Reported balance
After 2023-12-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-12-18 · Grant · Acquired 62,500 · Balance 526,516 F1: The Reporting person was awarded 62,500 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on June 1, 2024. F2: Includes 34,587 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on November 30, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting person was awarded 62,500 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on June 1, 2024.
F2: Includes 34,587 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on November 30, 2023.
CHINOOK THERAPEUTICS, INC.
Report date May 05, 2020 · Filed May 28, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2030-05-04 | Direct | 30,000 |
Reported balance
After 2020-05-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-05 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares subject to the Option will vest quarterly over one year from the grant date of May 5, 2020, such that the shares will be fully vested on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the Option will vest quarterly over one year from the grant date of May 5, 2020, such that the shares will be fully vested on the first anniversary of the date of grant.
Myovant Sciences Ltd.
Report date July 07, 2021 · Filed July 09, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 212,296 |
Reported balance
After 2021-07-07 transaction · row 1
1 source rowRow 1 · 2021-07-07 · Sale · Disposed 3,232 · Balance 212,296 F1: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. F2: The shares were sold at prices ranging from $21.75 to $21.83. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.
F2: The shares were sold at prices ranging from $21.75 to $21.83. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Phathom Pharmaceuticals, Inc.
Report date May 19, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 91,622 |
Reported balance
After 2026-05-19 transaction · row 1
1 source rowRow 1 · 2026-05-19 · Grant · Acquired 24,122 · Balance 91,622 F1: The Restricted Stock Units ("RSUs") were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units ("RSUs") were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cidara Therapeutics, Inc.
Report date January 07, 2026 · Filed January 08, 2026
Section 16 reporting ended · disclosed 2026-01-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-01-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-01-07 · Disposition to issuer · Disposed 7,526 · Balance 43,125 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the "Issuer"), Merck Sharp & Dohme LLC ("Merck") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck ("Purchaser"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a "Common Share") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share (each, a "Series A Share"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the "Merger"). [continues to Footnote 2] F2: [continues from Footnote 1] Pursuant to the terms of the Merger Agreement, Common Shares and Series A Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive (i) $221.50 per Common Share (the "Common Share Merger Consideration"), in cash, without interest, subject to any applicable withholding of taxes, and (ii) $15,505.00 per Series A Share (the "Series A Merger Consideration"), in cash, without interest, subject to any applicable withholding of taxes. [continues to Footnote 3] F3: [continues from Footnote 2] At the effective time of the Merger, each issued and outstanding Common Share and Series A Share (other than Common Shares (a) held by the Issuer (or in the Issuer's treasury), Merck, Purchaser, any other direct or indirect wholly owned subsidiary of Merck or the Issuer, or by stockholders of the Issuer who have properly exercised and perfected their statutory rights of appraisal, or (b) irrevocably accepted for purchase in the tender offer) was automatically canceled and converted into the right to receive the Common Share Merger Consideration and the Series A Merger Consideration, respectively, without interest and subject to any applicable withholding of taxes. F4: Includes 89 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan (ESPP) on December 18, 2025. Row 2 · 2026-01-07 · Disposition to issuer · Disposed 43,125 · Balance 0 F5: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding restricted stock unit award ("RSU"), whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to (i) the total number of Common Shares issuable in settlement of such RSU immediately prior to the effective time of the Merger multiplied by (ii) $221.50 per Common Share. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.50 · Expires 2035-02-23 | Direct | 0 |
Reported balance
After 2026-01-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-07 · Disposition to issuer · Disposed 115,000 · Balance 0 F6: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the "Issuer"), Merck Sharp & Dohme LLC ("Merck") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck ("Purchaser"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a "Common Share") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share (each, a "Series A Share"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the "Merger"). [continues to Footnote 2]
F2: [continues from Footnote 1] Pursuant to the terms of the Merger Agreement, Common Shares and Series A Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive (i) $221.50 per Common Share (the "Common Share Merger Consideration"), in cash, without interest, subject to any applicable withholding of taxes, and (ii) $15,505.00 per Series A Share (the "Series A Merger Consideration"), in cash, without interest, subject to any applicable withholding of taxes. [continues to Footnote 3]
F3: [continues from Footnote 2] At the effective time of the Merger, each issued and outstanding Common Share and Series A Share (other than Common Shares (a) held by the Issuer (or in the Issuer's treasury), Merck, Purchaser, any other direct or indirect wholly owned subsidiary of Merck or the Issuer, or by stockholders of the Issuer who have properly exercised and perfected their statutory rights of appraisal, or (b) irrevocably accepted for purchase in the tender offer) was automatically canceled and converted into the right to receive the Common Share Merger Consideration and the Series A Merger Consideration, respectively, without interest and subject to any applicable withholding of taxes.
F4: Includes 89 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan (ESPP) on December 18, 2025.
F5: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding restricted stock unit award ("RSU"), whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to (i) the total number of Common Shares issuable in settlement of such RSU immediately prior to the effective time of the Merger multiplied by (ii) $221.50 per Common Share.
F6: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 19, 2026 Filed May 21, 2026 20:30 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 24,122 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-234564 · ownership.xml · nonDerivative · entry 1 KARBE FRANK · CIK 0001276700 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,622 F1 · shares: The Restricted Stock Units ("RSUs") were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 01:16 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 115,000 | Not disclosed Strike: $20.50 | Not disclosed |
DisclosureSEC source: 0001276700-26-000002 · wk-form4_1767834957.xml · derivative · entry 3 KARBE FRANK · CIK 0001276700 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 115,000 shares Expires 2035-02-23 F6 · price: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. F6 · derivative.exercise_date: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 01:16 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | Disposition to issuerCommon Stock | 43,125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001276700-26-000002 · wk-form4_1767834957.xml · nonDerivative · entry 2 KARBE FRANK · CIK 0001276700 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F5 · kind: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding restricted stock unit award ("RSU"), whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to (i) the total number of Common Shares issuable in settlement of such RSU immediately prior to the effective time of the Merger multiplied by (ii) $221.50 per Common Share. F5 · price: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding restricted stock unit award ("RSU"), whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to (i) the total number of Common Shares issuable in settlement of such RSU immediately prior to the effective time of the Merger multiplied by (ii) $221.50 per Common Share. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 01:16 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | Disposition to issuerCommon Stock | 7,526 | $221.50 | $1,667,009.00 |
DisclosureSEC source: 0001276700-26-000002 · wk-form4_1767834957.xml · nonDerivative · entry 1 KARBE FRANK · CIK 0001276700 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,125 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the "Issuer"), Merck Sharp & Dohme LLC ("Merck") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck ("Purchaser"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a "Common Share") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share (each, a "Series A Share"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the "Merger"). [continues to Footnote 2] F2 · kind: [continues from Footnote 1] Pursuant to the terms of the Merger Agreement, Common Shares and Series A Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive (i) $221.50 per Common Share (the "Common Share Merger Consideration"), in cash, without interest, subject to any applicable withholding of taxes, and (ii) $15,505.00 per Series A Share (the "Series A Merger Consideration"), in cash, without interest, subject to any applicable withholding of taxes. [continues to Footnote 3] F3 · kind: [continues from Footnote 2] At the effective time of the Merger, each issued and outstanding Common Share and Series A Share (other than Common Shares (a) held by the Issuer (or in the Issuer's treasury), Merck, Purchaser, any other direct or indirect wholly owned subsidiary of Merck or the Issuer, or by stockholders of the Issuer who have properly exercised and perfected their statutory rights of appraisal, or (b) irrevocably accepted for purchase in the tender offer) was automatically canceled and converted into the right to receive the Common Share Merger Consideration and the Series A Merger Consideration, respectively, without interest and subject to any applicable withholding of taxes. F4 · shares: Includes 89 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan (ESPP) on December 18, 2025. Read SEC document |
| December 10, 2025 Filed Dec 13, 2025 00:41 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | Tax withholdingCommon Stock | 7,290 | $219.60 | $1,600,884.00 |
DisclosureSEC source: 0001610618-25-000102 · wk-form4_1765586504.xml · nonDerivative · entry 1 KARBE FRANK · CIK 0001276700 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,562 F1 · shares: Shares withheld for taxes on RSU vesting. F2 · balance_after: Includes 352 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan (ESPP) on November 20, 2025. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 20:58 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0000950170-25-082458 · ownership.xml · derivative · entry 2 KARBE FRANK · CIK 0001276700 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2035-06-02 F2 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 20:58 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-082458 · ownership.xml · nonDerivative · entry 1 KARBE FRANK · CIK 0001276700 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,500 F1 · shares: The Restricted Stock Units ("RSUs") were granted on June 3, 2025, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 23:31 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | GrantEmployee Stock Option (right to buy) · Derivative | 115,000 | $0.00 Strike: $20.50 | $0.00 |
DisclosureSEC source: 0001610618-25-000012 · wk-form4_1740612660.xml · derivative · entry 2 KARBE FRANK · CIK 0001276700 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2035-02-23 F2 · derivative.exercise_date: 25% of the shares subject to the option shall vest on the 1st anniversary of the vesting commencement date of February 24, 2025, and the balance of the shares shall vest in a series of 36 equal monthly installments measured from the 1st anniversary of the vesting commencement date, such that the option will be fully vested on February 24, 2029, subject to continuous service through each such vesting date. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 23:31 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | GrantCommon Stock | 57,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001610618-25-000012 · wk-form4_1740612660.xml · nonDerivative · entry 1 KARBE FRANK · CIK 0001276700 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,500 F1 · shares: Represents time-based Restricted Stock Units (RSUs) granted on February 24, 2025. All RSUs vest in four equal annual installments, with 1/4 vesting on each of March 10, 2026, 2027, 2028, and 2029, subject to continuous service through each such vesting date. Read SEC document |
| December 13, 2024 Filed Dec 16, 2024 13:05 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | PurchaseCommon Stock | 12,500 | $7.93 | $99,083.75 |
DisclosureSEC source: 0000950170-24-136391 · ownership.xml · nonDerivative · entry 1 KARBE FRANK · CIK 0001276700 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.87 to $8.00. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 29, 2024 Filed May 31, 2024 20:30 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 25,000 | $10.16 | $254,112.50 |
DisclosureSEC source: 0000950170-24-067365 · ownership.xml · nonDerivative · entry 1 KARBE FRANK · CIK 0001276700 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.1016 to $10.20. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 23, 2024 Filed May 24, 2024 23:33 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $10.30 | $0.00 |
DisclosureSEC source: 0000950170-24-064820 · ownership.xml · derivative · entry 2 KARBE FRANK · CIK 0001276700 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2034-05-22 F2 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date. Read SEC document |
| May 23, 2024 Filed May 24, 2024 23:33 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-064820 · ownership.xml · nonDerivative · entry 1 KARBE FRANK · CIK 0001276700 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,500 F1 · shares: The Restricted Stock Units ("RSUs") were granted on May 23, 2024, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 22:13 UTC | Better Therapeutics, Inc. BTTX · Entity 94385 | GrantCommon Stock | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-071939 · ownership.xml · nonDerivative · entry 1 KARBE FRANK · CIK 0001276700 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 526,516 F1 · shares: The Reporting person was awarded 62,500 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on June 1, 2024. F2 · balance_after: Includes 34,587 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on November 30, 2023. Read SEC document |
| July 27, 2023 Filed Jul 31, 2023 11:58 UTC | Better Therapeutics, Inc. BTTX · Entity 94385 | PurchaseCommon Stock | 137,005 | $0.73 | $99,999.95 |
DisclosureSEC source: 0000950170-23-035680 · ownership.xml · nonDerivative · entry 1 KARBE FRANK · CIK 0001276700 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 429,429 F1 · kind: On July 25, 2023, the Issuer entered into a Securities Purchase Agreement with certain investors (the "PIPE Investors") in a private placement offering, pursuant to which the PIPE Investors agreed to purchase shares of Issuer common stock for $0.7299 per share. F2 · kind: As one of the PIPE Investors, the Reporting Person acquired 137,005 shares of Issuer common stock on July 27, 2023 for $0.7299 per share. Read SEC document |
| May 25, 2023 Filed May 30, 2023 22:48 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $11.72 | $0.00 |
DisclosureSEC source: 0001209191-23-033007 · doc4.xml · derivative · entry 2 KARBE FRANK · CIK 0001276700 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-05-24 F2 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing in service on the Board through such vesting date. Read SEC document |
| May 25, 2023 Filed May 30, 2023 22:48 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033007 · doc4.xml · nonDerivative · entry 1 KARBE FRANK · CIK 0001276700 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 F1 · shares: The Restricted Stock Units ("RSUs") were granted on May 25, 2023, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| April 10, 2023 Filed Apr 12, 2023 20:15 UTC | Better Therapeutics, Inc. BTTX · Entity 94385 | PurchaseCommon Stock | 242,424 | $0.83 | $199,999.80 |
DisclosureSEC source: 0000899243-23-011189 · doc4.xml · nonDerivative · entry 1 KARBE FRANK · CIK 0001276700 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 292,424 F1 · kind: On April 6, 2023, the Issuer entered into a Securities Purchase Agreement with certain investors (the "PIPE Investors") in a private placement offering, pursuant to which the PIPE Investors agreed to purchase shares of Issuer common stock for $0.825 per share. As one of the PIPE Investors, the Reporting Person acquired 242,424 shares of Issuer common stock on April 10, 2023 for $0.825 per share. Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 00:53 UTC | Better Therapeutics, Inc. BTTX · Entity 94385 | PurchaseCommon Stock | 50,000 | $2.09 | $104,695.00 |
DisclosureSEC source: 0000899243-22-031206 · doc4.xml · nonDerivative · entry 1 KARBE FRANK · CIK 0001276700 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.06 to $2.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 20:32 UTC | Better Therapeutics, Inc. BTTX · Entity 94385 | GrantStock Option (Right to Buy) · Derivative | 472,200 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0000899243-22-025715 · doc4.xml · derivative · entry 1 KARBE FRANK · CIK 0001276700 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 472,200 Underlying: Common Stock · 472,200 shares Expires 2032-07-04 F1 · derivative.exercise_date: The stock option vests as to 1/4 of the shares subject to the stock option on July 5, 2023 and the remaining shares vest in 36 equal monthly installments thereafter, provided the Reporting Person continues to have a service relationship with Issuer on each vesting date. The stock option was granted on July 5, 2022. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:41 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.40 | $0.00 |
DisclosureSEC source: 0001209191-22-032578 · doc4.xml · derivative · entry 1 KARBE FRANK · CIK 0001276700 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-05-24 F1 · derivative.exercise_date: The stock option will vest with respect to one-third of the shares of common stock on April 25, 2023, and will vest in substantially equal quarterly installments over the twenty-four (24) months thereafter, subject to the Reporting Person's continuous service to the Issuer on the applicable vesting dates. Read SEC document |
| April 25, 2022 Filed Apr 26, 2022 21:21 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $13.61 | $0.00 |
DisclosureSEC source: 0001209191-22-025660 · doc4.xml · derivative · entry 1 KARBE FRANK · CIK 0001276700 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-04-24 F1 · derivative.exercise_date: The stock option will vest with respect to one-third of the shares of common stock on April 25, 2023, and will vest in substantially equal quarterly installments over the twenty-four (24) months thereafter, subject to the reporting person's continuous service to the Issuer on the applicable vesting dates. Read SEC document |
| July 07, 2021 Filed Jul 9, 2021 20:27 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Shares | 3,232 | $21.75 | $70,296.00 |
DisclosureSEC source: 0001209191-21-046171 · doc4.xml · nonDerivative · entry 1 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,296 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. F2 · price: The shares were sold at prices ranging from $21.75 to $21.83. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 20:17 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 97,534 | $0.00 Strike: $17.88 | $0.00 |
DisclosureSEC source: 0001209191-21-027281 · doc4.xml · derivative · entry 2 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,534 Underlying: Common Shares · 97,534 shares Expires 2031-04-14 F2 · derivative.exercise_date: 1/4 of the common shares underlying this option vest on April 15, 2022, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 20:17 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantCommon Shares | 63,138 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-027281 · doc4.xml · nonDerivative · entry 1 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,528 F1 · shares: The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units ("RSUs") granted to the Reporting Person. 1/4 of the common shares underlying the RSUs vest on April 15, 2022, and 1/16 of the common shares underlying the RSUs vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| April 06, 2021 Filed Apr 8, 2021 20:55 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Shares | 11,080 | $18.63 | $206,420.40 |
DisclosureSEC source: 0001209191-21-026084 · doc4.xml · nonDerivative · entry 1 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,390 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. F2 · price: The shares were sold at prices ranging from $18.60 to $19.04. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 21:52 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionStock Option (Right to Buy) · Derivative | 750 | $0.00 Strike: $5.11 | $0.00 |
DisclosureSEC source: 0001209191-21-011894 · doc4.xml · derivative · entry 3 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,744 Underlying: Common Shares · 750 shares Expires 2026-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 21:52 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Shares | 750 | $21.40 | $16,050.00 |
DisclosureSEC source: 0001209191-21-011894 · doc4.xml · nonDerivative · entry 2 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,470 F1 · shares: Shares sold pursuant to a 10b5-1 trading plan. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 21:52 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionCommon Shares | 750 | $5.11 | $3,832.50 |
DisclosureSEC source: 0001209191-21-011894 · doc4.xml · nonDerivative · entry 1 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2021 Filed Feb 1, 2021 21:29 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionStock Option (Right to Buy) · Derivative | 300 | $0.00 Strike: $5.11 | $0.00 |
DisclosureSEC source: 0001209191-21-006444 · doc4.xml · derivative · entry 3 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,494 Underlying: Common Shares · 300 shares Expires 2026-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| January 28, 2021 Filed Feb 1, 2021 21:29 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Shares | 300 | $24.00 | $7,200.00 |
DisclosureSEC source: 0001209191-21-006444 · doc4.xml · nonDerivative · entry 2 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,470 F1 · shares: Shares sold pursuant to a 10b5-1 trading plan. Read SEC document |
| January 28, 2021 Filed Feb 1, 2021 21:29 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionCommon Shares | 300 | $5.11 | $1,533.00 |
DisclosureSEC source: 0001209191-21-006444 · doc4.xml · nonDerivative · entry 1 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,770 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 21:39 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionStock Option (Right to Buy) · Derivative | 750 | $0.00 Strike: $5.11 | $0.00 |
DisclosureSEC source: 0001209191-21-004328 · doc4.xml · derivative · entry 3 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,794 Underlying: Common Shares · 750 shares Expires 2026-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 21:39 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Shares | 750 | $21.50 | $16,125.00 |
DisclosureSEC source: 0001209191-21-004328 · doc4.xml · nonDerivative · entry 2 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,470 F1 · shares: Shares sold pursuant to a 10b5-1 trading plan. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 21:39 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionCommon Shares | 750 | $5.11 | $3,832.50 |
DisclosureSEC source: 0001209191-21-004328 · doc4.xml · nonDerivative · entry 1 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 21:29 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,800 | $0.00 Strike: $5.11 | $0.00 |
DisclosureSEC source: 0001209191-20-065511 · doc4.xml · derivative · entry 3 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,544 Underlying: Common Shares · 11,800 shares Expires 2026-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 21:29 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Shares | 11,800 | $30.00 | $354,000.00 |
DisclosureSEC source: 0001209191-20-065511 · doc4.xml · nonDerivative · entry 2 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,470 F1 · shares: Shares sold pursuant to a 10b5-1 trading plan. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 21:29 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionCommon Shares | 11,800 | $5.11 | $60,298.00 |
DisclosureSEC source: 0001209191-20-065511 · doc4.xml · nonDerivative · entry 1 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,270 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 21:51 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,050 | $0.00 Strike: $5.11 | $0.00 |
DisclosureSEC source: 0001209191-20-064096 · doc4.xml · derivative · entry 4 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,344 Underlying: Common Shares · 1,050 shares Expires 2026-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 21:51 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Stock | 670 | $24.45 | $16,382.51 |
DisclosureSEC source: 0001209191-20-064096 · doc4.xml · nonDerivative · entry 3 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,470 F1 · shares: Shares sold pursuant to a 10b5-1 trading plan. F3 · price: The shares were sold at prices ranging from $24.05 to $24.75. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 21:51 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Shares | 380 | $23.63 | $8,980.20 |
DisclosureSEC source: 0001209191-20-064096 · doc4.xml · nonDerivative · entry 2 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,140 F1 · shares: Shares sold pursuant to a 10b5-1 trading plan. F2 · price: The shares were sold at prices ranging from $23.05 to $24.03. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 21:51 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionCommon Shares | 1,050 | $5.11 | $5,365.50 |
DisclosureSEC source: 0001209191-20-064096 · doc4.xml · nonDerivative · entry 1 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,520 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 22:08 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $5.11 | $0.00 |
DisclosureSEC source: 0001209191-20-061221 · doc4.xml · derivative · entry 3 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,394 Underlying: Common Shares · 1,500 shares Expires 2026-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 22:08 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Shares | 1,500 | $24.00 | $36,000.00 |
DisclosureSEC source: 0001209191-20-061221 · doc4.xml · nonDerivative · entry 2 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,470 F1 · shares: Shares sold pursuant to a 10b5-1 trading plan. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 22:08 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionCommon Shares | 1,500 | $5.11 | $7,665.00 |
DisclosureSEC source: 0001209191-20-061221 · doc4.xml · nonDerivative · entry 1 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,970 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 22:04 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionStock Option (Right to Buy) · Derivative | 750 | $0.00 Strike: $5.11 | $0.00 |
DisclosureSEC source: 0001209191-20-059450 · doc4.xml · derivative · entry 3 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,894 Underlying: Common Shares · 750 shares Expires 2026-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 22:04 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Shares | 750 | $20.00 | $15,000.00 |
DisclosureSEC source: 0001209191-20-059450 · doc4.xml · nonDerivative · entry 2 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,470 F1 · shares: Shares sold pursuant to a 10b5-1 trading plan. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 22:04 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionCommon Shares | 750 | $5.11 | $3,832.50 |
DisclosureSEC source: 0001209191-20-059450 · doc4.xml · nonDerivative · entry 1 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2020 Filed Nov 17, 2020 23:50 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionStock Option (Right to Buy) · Derivative | 750 | $0.00 Strike: $5.11 | $0.00 |
DisclosureSEC source: 0001209191-20-058894 · doc4.xml · derivative · entry 3 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,644 Underlying: Common Shares · 750 shares Expires 2026-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| November 13, 2020 Filed Nov 17, 2020 23:50 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Shares | 750 | $20.00 | $15,000.00 |
DisclosureSEC source: 0001209191-20-058894 · doc4.xml · nonDerivative · entry 2 KARBE FRANK · CIK 0001276700 · Principal Fin'l & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,470 F1 · shares: Shares sold pursuant to a 10b5-1 trading plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.